tetano
Editor, Senior Moderator
Biotechnol J. 2017 Dec 26. doi: 10.1002/biot.201700645. [Epub ahead of print]
[h=1]Monophosphoryl lipid A-adjuvanted virosomes with Ni-chelating lipids for attachment of conserved viral proteins as cross-protective influenza vaccine.[/h] Dong W[SUP]1,[/SUP][SUP]2[/SUP], Bhide Y[SUP]1[/SUP], Marsman S[SUP]1[/SUP], Holtrop M[SUP]1[/SUP], Meijerhof T[SUP]1[/SUP], de Vries-Idema J[SUP]1[/SUP], de Haan A[SUP]1[/SUP], Huckriede A[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Induction of CD8[SUP]+[/SUP] cytotoxic T cells (CTLs) to conserved internal influenza antigens, such as nucleoprotein (NP), is a promising strategy for the development of cross-protective influenza vaccines. However, influenza NP protein alone cannot induce CTL immunity due to its low capacity to activate antigen-presenting cells (APCs) and get access to the MHC class I antigen processing pathway.
[h=4]METHODS:[/h] To facilitate the generation of NP-specific CTL immunity we developed a novel influenza vaccine consisting of virosomes with the Toll-like receptor 4 (TLR4) ligand monophosphoryl lipid A (MPLA) and the metal-ion-chelating lipid DOGS-NTA-Ni incorporated in the membrane.
[h=4]RESULTS:[/h] In vitro, virosomes with incorporated MPLA induced stronger activation of APCs than unadjuvanted virosomes. Virosomes modified with DOGS-NTA-Ni showed high conjugation efficacy for his-tagged proteins and facilitated efficient uptake of conjugated proteins by APCs. Immunization of mice with MPLA-adjuvanted virosomes with attached NP resulted in priming of NP-specific CTLs while MPLA-adjuvanted virosomes with admixed NP were inefficient in priming CTLs. Both vaccines induced equally high titers of NP-specific antibodies. When challenged with heterosubtypic influenza virus, mice immunized with virosomes with attached or admixed NP were protected from severe weight loss. Yet, unexpectedly, they showed more weight loss and more severe disease symptoms than mice immunized with MPLA-virosomes without NP.
[h=4]CONCLUSIONS:[/h] Taken together, these results indicate that virosomes with conjugated antigen and adjuvant incorporated in the membrane are effective in priming of CTLs and eliciting antigen-specific antibody responses in vivo. However, for protection from influenza infection NP-specific immunity appeared not to be advantageous.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] CD8+ T cells; MPLA; NP; Virosomes; cross-protection
PMID: 29278302 DOI: 10.1002/biot.201700645
[h=1]Monophosphoryl lipid A-adjuvanted virosomes with Ni-chelating lipids for attachment of conserved viral proteins as cross-protective influenza vaccine.[/h] Dong W[SUP]1,[/SUP][SUP]2[/SUP], Bhide Y[SUP]1[/SUP], Marsman S[SUP]1[/SUP], Holtrop M[SUP]1[/SUP], Meijerhof T[SUP]1[/SUP], de Vries-Idema J[SUP]1[/SUP], de Haan A[SUP]1[/SUP], Huckriede A[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Induction of CD8[SUP]+[/SUP] cytotoxic T cells (CTLs) to conserved internal influenza antigens, such as nucleoprotein (NP), is a promising strategy for the development of cross-protective influenza vaccines. However, influenza NP protein alone cannot induce CTL immunity due to its low capacity to activate antigen-presenting cells (APCs) and get access to the MHC class I antigen processing pathway.
[h=4]METHODS:[/h] To facilitate the generation of NP-specific CTL immunity we developed a novel influenza vaccine consisting of virosomes with the Toll-like receptor 4 (TLR4) ligand monophosphoryl lipid A (MPLA) and the metal-ion-chelating lipid DOGS-NTA-Ni incorporated in the membrane.
[h=4]RESULTS:[/h] In vitro, virosomes with incorporated MPLA induced stronger activation of APCs than unadjuvanted virosomes. Virosomes modified with DOGS-NTA-Ni showed high conjugation efficacy for his-tagged proteins and facilitated efficient uptake of conjugated proteins by APCs. Immunization of mice with MPLA-adjuvanted virosomes with attached NP resulted in priming of NP-specific CTLs while MPLA-adjuvanted virosomes with admixed NP were inefficient in priming CTLs. Both vaccines induced equally high titers of NP-specific antibodies. When challenged with heterosubtypic influenza virus, mice immunized with virosomes with attached or admixed NP were protected from severe weight loss. Yet, unexpectedly, they showed more weight loss and more severe disease symptoms than mice immunized with MPLA-virosomes without NP.
[h=4]CONCLUSIONS:[/h] Taken together, these results indicate that virosomes with conjugated antigen and adjuvant incorporated in the membrane are effective in priming of CTLs and eliciting antigen-specific antibody responses in vivo. However, for protection from influenza infection NP-specific immunity appeared not to be advantageous.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] CD8+ T cells; MPLA; NP; Virosomes; cross-protection
PMID: 29278302 DOI: 10.1002/biot.201700645